References
- Longo D.L. The use of chemotherapy in the treatment of Hodgkin's disease. Sem Oncol 1990; 17: 716–735
- Longo D.L., Duffey P.L., Young R.C., et al. Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy. The low probability of cure. J Clin Oncol 1992; 10: 210–218
- Bierman P.J., Bagin R.G., Jagannath S., et al. High-dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease. Long-term follow-up of 128 patients. Ann Oncol 1993; 4: 767–771
- Fuchs R., Löeffler M., Pfreuncschuh G., et al. Prognosis of high-dose chemotherapy autologous bone marrow transplation candidates no receiving this treatment after failure of primary therapy of Hodgkin's disease. Leuk Lymph 1994; 14: 79–89
- Miller D.S., Arthur D.L., Litz L.E., et al. Myelodysplastic syndrome after autologous bone marrow transplantation. An additional late complication of curative cancer therapy. Blood 1994; 83: 3780–3786
- Traweek S.T., Slovack M.L., Nadena E.E., et al. Myelodysplasia and acute myeloid leukemia ocurring after autologous bone marrow transplantation for lymphoma. Leuk Lymp 1996; 20: 365–372
- Avilés A., Arévila N., Díaz-Maqueo J.C., et al. Late cardiac toxicity of doxorubicin, epirubicin and mitoxantrone therapy for Hodgkin's disease in adults. Leuk Lymph 1993; 11: 275–279
- Leavitt R.D., Ratanatharatorn V., Ozer J., et al. Alfa 2b interferon in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma. Sem Oncol 1987; 14(Suppl 2)8–23
- Ryback M., McCarroll K., Bernard S. Interferon therapy of relapsed and refractory Hodgkin's disease. J Biol Respons Mod 1990; 9: 1–4
- DelCarmen M., Koziner B., Niborski R. Recombinant interferon alfa 2b in patients with progressive and/or recurrent Hodgkin's disease. Leuk Lymph 1991; 3: 439–441
- Atspodier J., Kircher H. The outpatient use of recombinant human interleukin 2 and interferon alfa 2b in advances malignancies. Eur J Cancer 1991; 27(Suppl 4)88–92
- Mazza P., Zinzani P.L., Pappa G., et al. Alpha 2b recombinant interferon (Intron A in Hodgkin's lymphoma. Eur J Haematol 1993; 45(Suppl 45)22–24
- Lukes R.J., Butler J.J. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966; 26: 1063–1083
- Carbone P., Kaplan H.S., Mushoff K., Smithers D.W., Tubiana M. Report of the Committee on Hodgkin's disease. Staging classification. Cancer Res 1976; 38: 288–301
- Avilés A., Díaz-Maqueo J.C., Arévila N., et al. Valoración de la funcion ventricular en pacientes tratados con mitoxantrone y epirubicina. Arch Inst Cardiol Mex 1989; 59: 615–618
- Avilés A., Guzmán R., Talavera A., García E.L., Díaz-Maqueo J.C. Randomised study for the treatment of adult advanced Hodgkin's disease: epirubicin, vinblastine, bleomycin and dacarbazine (EBVD) versus mitoxantrone, vinblastine, bleomycin and dacarbazine (MBVD). Med Pediatr Oncol 1994; 22: 168–172
- Kaplan E.L., Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
- Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170
- World Health Organization. WHO Handbook for Reporting results of cancer treatment. WHO Offset Publications No 48, GenevaSwitzerland 1979
- Avilés A., Fernández R., Talavera A., Guzmán R. The role of G-CSF as hematological support after myeloablative chemotherapy for refractory Hodgkin's disease. Cancer Res Ther Control 1995; 4: 241–245
- Yahalom R., Ryi J., Strauss D.J., et al. Impact of adjuvant radiation on the patterns and rate of relapse in advanced stage Hodgkin's disease treated with alternating chemotherapy combination. J Clin Oncol 1991; 9: 2193–2201
- Somers R., Carde P., Henry-Amar M., et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight course of MOPP versus alternation of MOPP with ABVD. An European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre et Marie-Curie controlled clinical trial. J Clin Oncol 1994; 12: 279–287
- Avilés A., Díaz-Maqueo J.C., Garcia E.L., Talavera A., Guzmán R. Maintenance therapy with interferon alfa 2b in patients with diffuse large cell lymphoma. Invest New Drugs 1992; 10: 351–355